Holen Sie sich die Stockscreener-App
0.8962
2.48%
-0.0228
Vorhandelsmarkt:
.91
0.0138
+1.54%
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights - Lelezard
Akebia Therapeutics, Inc. $AKBA Position Reduced by State Street Corp - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Stock Price, News, Quote & History - Yahoo! Finance Canada
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Exploring A 337% Potential Upside - DirectorsTalk Interviews
BTIG Research Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Akebia Therapeutics Price Target Maintained With a $4.00/Share by BTIG - Moomoo
Akebia doses first patient in Phase 2 kidney disease trial By Investing.com - Investing.com South Africa
Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial - marketscreener.com
Akebia doses first patient in Phase 2 kidney disease trial - Investing.com
One trial, three rare kidney diseases: Akebia doses its first patient - Stock Titan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Recommendation of "Hold" by Brokerages - marketbeat.com
Akebia Therapeutics (NASDAQ:AKBA) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
CRM: Salesforce Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
AKBA Initiates Coverage On WestPark Capital -- Rating Set to Buy - GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital - marketbeat.com
BlackRock Inc. Buys Shares of 19,986,374 Akebia Therapeutics, Inc. $AKBA - marketbeat.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - marketscreener.com
Nantahala Capital Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Akebia (AKBA) Market: Slides 1.39% to $0.91 for the Current Session; Key Range: the Near-Term Reference Band Stretches From $0.86 to $0.96 on the DayRTH Profile - vinanet.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Analysts - MarketBeat
Akebia Therapeutics, Inc. Revenue Breakdown – NASDAQ:AKBA - TradingView
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 33.18%Earnings Preview - dars.gov.et
Akebia Therapeutics CEO John P. Butler Exercises 350,000 Stock Options at $0.63 Each - Kalkine Media
Weekly Recap: Vafseo sales surge and ebribafusp Phase 2 trial start - TradingView
Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC - MarketBeat
HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings - MarketBeat
Akebia Therapeutics (AKBA) AGM 2026 Summary - Quartr
Akebia Therapeutics Price Target Announced at $1.00/Share by Leerink Partners - Moomoo
Akebia Therapeutics Inc (AKBA) Stock News Today - TradingKey
Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform" - MarketBeat
Akebia Therapeutics Inc (AKBA:UR): Stock Price, Quote and News - BNN Bloomberg
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: Analyzing a 340% Potential Upside Amid Healthcare Innovation - DirectorsTalk Interviews
AKBA Q2 2026 Earnings: 55.5% EPS Surprise on Narrower Loss, Yet Shares Slide 4.66%Operating Income Trends - dars.gov.et
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
AKBA Looks 1.6% Overvalued on GF Value™ - GuruFocus
AKBA Looks 1.2% Overvalued on GF Value™ as Market Prices in Mode - GuruFocus
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlight - GuruFocus
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ... - Yahoo Finance
Is Akebia Therapeutics Inc (AKBA) Overvalued After Q2 Earnings M - GuruFocus
Akebia Therapeutics Q2 Earnings Call Highlights - MarketBeat
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Akebia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results - MarketBeat
Akebia Therapeutics: Q2 Earnings Snapshot - Barchart.com
Akebia Therapeutics Inc. R (AX9.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Akebia Therapeutics 2Q 2026: Revenue $49.1M, EPS $(0.03) — 10-Q Summary - TradingView
Akebia begins trial for three rare kidney diseases; data expected in 2027 - Stock Titan
AKBA: Vafseo's strong growth offset Auryxia's decline, but total revenues and net income fell year-over-year - TradingView
Akebia Therapeutics Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
0.18%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):